{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-002434","form_type":"8-K","ticker":null,"cik":"0001260990","company_name":"Oncternal Therapeutics, Inc.","filed_at":"2024-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.628751+00:00","generated_at":"2026-06-07T02:57:35.129716+00:00","sec_items":["2.02","3.03","5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Oncternal pre-announces $34.3M cash; 20:1 reverse stock split effective Jan 8","bullets":["Preliminary cash and cash equivalents of $34.3M as of Dec 31, 2023; subject to closing procedures.","Shares outstanding: ~59.2M pre-split; ~3.0M post-split after 20:1 reverse stock split.","Reverse stock split effective 12:01 a.m. ET on Jan 8, 2024; new CUSIP 68236P206.","No fractional shares issued; fractional holders receive proportional cash payment.","Exercise prices and share counts for stock options and warrants adjusted proportionally."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-002434","json":"https://secwatch.observer/filing/0000950170-24-002434.json","markdown":"https://secwatch.observer/filing/0000950170-24-002434.md","text":"https://secwatch.observer/filing/0000950170-24-002434.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1260990/000095017024002434/0000950170-24-002434-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1260990/000095017024002434/onct-20240103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:57:35.129716+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5735baeca2b23f9e3fc9ff5b1c49b92b4b320450","claim":"Oncternal Therapeutics, Inc. reported preliminary financial results for as of December 31, 2023.","evidence_excerpt":"Oncternal Therapeutics, Inc. (“Oncternal”) estimates that, as of December 31, 2023, its cash and cash equivalents were $34.3 million and it had 59.2 million shares of common stock, par value $0.001 per share (“Common Stock”) outstanding, or 3.0 million shares of Common Stock after giving effect to the Reverse Stock Split (defined below). These amounts are preliminary and are subject to completion of financial closing procedures.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1260990/000095017024002434/0000950170-24-002434-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"as of December 31, 2023"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"56ee1f398dab06bf07eaae2495361e6441476be9","claim":"Oncternal Therapeutics, Inc.: Amended restated certificate of incorporation to effect a 1-for-20 reverse stock split (effective 2024-01-08).","evidence_excerpt":"On January 3, 2024, Oncternal filed an amendment (the “Amendment”) to its restated certificate of incorporation to effectuate a reverse stock split of Oncternal’s Common Stock.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1260990/000095017024002434/0000950170-24-002434-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-01-08"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}